In the Clinic: Metabolic dysfunction-associated steatotic liver disease
A recent article described the risk factors for metabolic dysfunction-associated liver disease, along with screening and prevention, diagnosis, management and treatment, and practice improvement.
An In the Clinic article published by Annals of Internal Medicine on Jan. 14 provided an overview of metabolic dysfunction-associated liver disease (MASLD).
The article discussed risk factors, screening and prevention, diagnosis, management and treatment, and practice improvement. It noted that MASLD is defined as the presence of liver steatosis with at least one of five cardiometabolic risk factors: obesity, central obesity, insulin resistance, hypertension, and dyslipidemia. The “MASLD” nomenclature was introduced in June 2023 and replaces “NAFLD” or “nonalcoholic fatty liver disease,” which had been defined as the presence of liver steatosis in more than 5% of hepatocytes in the absence of alcohol consumption above a certain threshold (20 g/d in women and 30 g/d in men), the article explained.
The editors of Annals develop In the Clinic with the assistance of additional physician writers, MKSAP, and other resources of ACP.